{
  "id": 11741587,
  "title": "Novartis wagers almost $8B on a Chinese biotech’s RNA drugs",
  "url": "https://urgent.news/2026/10/02/novartis-wagers-almost-8b-on-a-chinese-biotechs-rna-drugs",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-10-02T14:16:54.000Z",
  "source": {
    "name": "BioPharma Dive",
    "slug": "biopharma-dive",
    "url": "https://www.biopharmadive.com/news/novartis-abogen-pipeline-collaboration-china/832008/"
  },
  "original_language": "en",
  "account": null,
  "summary": "In exchange for a $575 million payment up front, Abogen Biosciences will furnish Novartis with access to its RNA technology, including an option to license its lead program ABO-2203.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}